pISSN 1226-6051
eISSN 2508-786X

Table. 1.

Table. 1.

Clinical characteristics of patient with T2DM on antidiabetic monotherapy, 2003-2013

MetforminSulfonylureaOthersTotalp-value
N (%)5825 (60.97%)3225 (33.76%)504 (5.28%)9554 (100%)
Age (years)
 30-39194 (3.33%)52 (1.61%)16 (3.17%)262 (2.74%)
 40-49790 (13.56%)284 (8.81%)60 (11.90%)1134 (11.87%)
 50-591654 (28.39%)651 (20.19%)99 (19.64%)2404 (25.16%)<0.0001
 60-691723 (29.58%)1063 (32.96%)157 (31.15%)2943 (30.80%)
 70-791195 (20.52%)879 (27.26%)123 (24.40%)2197 (23.00%)
 ≥ 80269 (4.62%)296 (9.18%)49 (9.72%)614 (6.43%)
Sex
 Woman2988 (51.30%)1620 (50.23%)234 (46.43%)4842 (50.68%)0.3019
 Man2837 (48.70%)1605 (49.77%)270 (53.57%)4712 (49.32%)
Charlson comorbidity index (CCI)
Median (IQR)1.0 (1.0)1.0 (1.0)2.0 (2.0)1.0 (1.0)<0.0001
 0586 (10.06%)532 (16.50%)61 (12.10%)1179 (12.34%)
 12911 (49.97%)1215 (37.67%)165 (32.74%)4291 (44.91%)
 21411 (24.22%)735 (22.79%)126 (25.00%)2272 (23.78%)
 3551 (9.46%)345 (10.70%)62 (12.30%)958 (10.03%)<0.0001
 4216 (3.71%)201 (6.23%)35 (6.94%)452 (4.73%)
 578 (1.34%)97 (3.01%)15 (2.98%)190 (1.99%)
 629 (0.50%)37 (1.15%)16 (3.17%)82 (0.86%)
 ≥743 (0.73%)63 (1.95%)24 (4.77%)130 (1.36%)
Comorbidities
 Hyperlipidemia4529 (77.75%)1709 (52.99%)364 (72.22%)6602 (69.10%)<0.0001
 Hypertension4291 (73.67%)2411 (74.76%)386 (76.59%)7088 (74.19%)0.2349
 Pancreatitis254 (4.36%)111 (3.44%)45 (8.93%)410 (4.29%)<0.0001
 Morbid obesity12 (0.13%)1 (0.03%)0 (0.00%)13 (0.14%)0.0115
 Alcohol use83 (1.42%)41 (1.27%)19 (3.77%)143 (1.50%)<0.0001
 Smoking7 (0.12%)2 (0.06%)2 (0.40%)11 (0.12%)0.1176
Duration of follow-up (years), Median (Interquartile range)
Median (IQR*)1.74 (0.75-3.08)3.21 (1.22-5.92)1.31 (0.58-3.55)2.04 (0.84-4.02)<0.0001
 ≤34297 (73.77%)1523 (47.23%)353 (70.05%)6173 (64.61%)
 >3 to ≤5900 (15.45%)678 (21.02%)69 (13.69%)1647 (17.24%)
 >5 to ≤7369 (6.34%)425 (13.18%)37 (7.35%)831 (8.70%)<0.0001
 >7 to ≤9150 (2.58%)289 (8.96%)22 (4.36%)461 (4.83%)
 >9109 (1.87%)310 (9.61%)23 (4.57%)442 (4.62%)

IQR: interquartile range

Korean J Clin Pharm 2019;29:186-92 https://doi.org/10.24304/kjcp.2019.29.3.186
© 2019 Korean J Clin Pharm